Galectin Therapeutics (GALT) Times Interest Earned (2018 - 2026)
Galectin Therapeutics (GALT) posted quarterly Times Interest Earned of -$2.05 for Q1 2026, up 54.71% year-over-year from -$1.33 in Q1 2025, and down 342.95% quarter-over-quarter from -$0.46 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Times Interest Earned (2018 - 2026) Analysis & Trends
Galectin Therapeutics' Times Interest Earned history runs 16 years deep, the most recent figure standing at -$2.05 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 54.71% year-over-year to -$2.05; the TTM figure through Mar 2026 stood at -$1.26 (up 68.87% YoY), while the FY2025 annual figure was -$0.21, up 55.3% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$2.05, down from -$0.46 in the prior quarter.
- The five-year high for Times Interest Earned was -$0.46 in Q4 2025, with the low at -$173.84 in Q4 2023.
- The 5-year median for Times Interest Earned is -$9.17 (2024), against an average of -$22.68.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned plunged 1343.6% in 2023, then surged 98.71% in 2024.
- Galectin Therapeutics' Times Interest Earned stood at -$12.04 in 2022, then sank by 1343.6% to -$173.84 in 2023, then soared by 98.71% to -$2.24 in 2024, then jumped by 79.36% to -$0.46 in 2025, then tumbled by 342.95% to -$2.05 in 2026.
- Business Quant data shows GALT's Times Interest Earned at -$2.05 in Q1 2026, -$0.46 in Q4 2025, and -$2.31 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | -1.99 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.99 |
| Mar 31, 2026 | -2.05 |
| Dec 31, 2025 | -1.74 |
| Sep 30, 2025 | -2.31 |
| Jun 30, 2025 | -2.53 |
| Mar 31, 2025 | -4.53 |
| Dec 31, 2024 | -7.20 |
| Sep 30, 2024 | -6.07 |
| Jun 30, 2024 | -8.90 |
| Mar 31, 2024 | -9.17 |
| Dec 31, 2023 | -11.29 |
| Sep 30, 2023 | -10.98 |
| Jun 30, 2023 | -13.85 |
| Mar 31, 2023 | -22.48 |
| Dec 31, 2022 | -34.52 |
| Sep 30, 2022 | -30.19 |
| Jun 30, 2022 | -40.09 |
| Mar 31, 2022 | -43.77 |
| Dec 31, 2021 | -27.30 |
| Sep 30, 2021 | -74.27 |